This brand name is authorized in United Kingdom
The drug OPILON contains one active pharmaceutical ingredient (API):
|
1
Moxisylyte
UNII WK2KZM9V6X - MOXISYLYTE HYDROCHLORIDE
|
|
Moxisylyte is an alpha-adrenergic blocking agent which is used for the treatment of the symptoms of Raynaud’s phenomenon. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| OPILON Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C04AX10 | Moxisylyte | C Cardiovascular system → C04 Peripheral vasodilators → C04A Peripheral vasodilators → C04AX Other peripheral vasodilators |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: GB | Medicines & Healthcare Products Regulatory Agency | Identifier(s): 36680 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
